title: A Review of Treatment Options for Progressive Supranuclear Palsy.
abstract: Progressive supranuclear palsy (PSP) is an atypical parkinsonian condition characterized by a symmetric akinetic-rigid syndrome, early falls, supranuclear gaze palsy, and a frontotemporal behavioral syndrome. The typical phenotype is termed Richardson's syndrome, but numerous other phenotypes have been described. The pathophysiology of PSP is not fully understood, but dysfunction of the tau protein seems to play a central role. Despite exciting new knowledge on the pathophysiology of PSP, there is still no highly effective symptomatic or disease-modifying treatment. We review the evidence on pharmacotherapy and experimental therapies in PSP and provide levels of recommendation for the off-label use of commonly used drugs in this disorder.
authors.affiliation: Department of Neurology, Philipps University, Marburg, Germany. mariastamelou@gmail.com.|Movement Disorders Department, HYGEIA Hospital, Athens, Greece. mariastamelou@gmail.com.|Second Department of Neurology, Attikon University Hospital, University of Athens, Rimini 1, Athens, Greece. mariastamelou@gmail.com.
authors.forename: Maria
authors.initials: M
authors.lastname: Stamelou
authors.affiliation: Department of Neurology, Philipps University, Marburg, Germany.|Department of Neurology, Technische Universität München, Munich, Germany.|German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
authors.forename: Günter
authors.initials: G
authors.lastname: Höglinger
mesh_terms: D015259:Dopamine Agents / Q000627:therapeutic use*; D006801:Humans; D015201:Meta-Analysis as Topic; D056687:Off-Label Use; D013494:Supranuclear Palsy, Progressive / Q000188:drug therapy*; D016896:Treatment Outcome; D016875:tau Proteins / Q000378:metabolism*
chemical_list: D015259:Dopamine Agents; D016875:tau Proteins